Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry

Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry

Abstract Background Treatment persistence is an important consideration when selecting a therapy for chronic conditions such as rheumatoid arthritis (RA). We assessed the long-term persistence of abatacept or a tumor necrosis factor inhibitor (TNFi) following (1) inadequate response to a conventiona...

Full description

Bibliographic Details
Main Authors: Denis Choquette, Louis Bessette, Evo Alemao, Boulos Haraoui, Roelien Postema, Jean-Pierre Raynauld, Louis Coupal
Format: Article
Language:English
Published: BMC 2019-06-01
Series:Arthritis Research & Therapy
Subjects:
Rheumatoid arthritis
Registry
Disease-modifying antirheumatic drugs (biologic)
Persistence
Abatacept
TNF inhibitor
Online Access:http://link.springer.com/article/10.1186/s13075-019-1917-8

Internet

http://link.springer.com/article/10.1186/s13075-019-1917-8

Similar Items